Maureane Hoffman

List of Publications by Year
in descending order

193 papers	13,225 citations	25034 57 h-index	23533 111 g-index
198 all docs	198 docs citations	198 times ranked	9055 citing authors

#	Article	IF	Citations
1	A Cell-based Model of Hemostasis. Thrombosis and Haemostasis, 2001, 85, 958-965.	3.4	1,286
2	Platelets and Thrombin Generation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1381-1389.	2.4	579
3	Platelet activity of highâ€dose factor VIIa is independent of tissue factor. British Journal of Haematology, 1997, 99, 542-547.	2.5	557
4	Platelet functions beyond hemostasis. Journal of Thrombosis and Haemostasis, 2009, 7, 1759-1766.	3.8	465
5	A Systematic Evaluation of the Effect of Temperature on Coagulation Enzyme Activity and Platelet Function. Journal of Trauma, 2004, 56, 1221-1228.	2.3	424
6	The Effect of Temperature and pH on the Activity of Factor VIIa: Implications for the Efficacy of High-Dose Factor VIIa in Hypothermic and Acidotic Patients. Journal of Trauma, 2003, 55, 886-891.	2.3	415
7	A cell-based model of hemostasis. Thrombosis and Haemostasis, 2001, 85, 958-65.	3.4	348
8	What Does It Take to Make the Perfect Clot?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 41-48.	2.4	341
9	Trauma-induced coagulopathy. Nature Reviews Disease Primers, 2021, 7, 30.	30.5	300
10	Remodeling the Blood Coagulation Cascade. Journal of Thrombosis and Thrombolysis, 2003, 16, 17-20.	2.1	277
11	A cell-based model of coagulation and the role of factor VIIa. Blood Reviews, 2003, 17, S1-S5.	5.7	244
12	Generation of Species Cross-reactive Aptamers Using â€œToggleâ€•SELEX. Molecular Therapy, 2001, 4, 567-573.	8.2	239
13	Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2.. Journal of Clinical Investigation, 1998, 102, 1994-2001.	8.2	231
14	Coagulation 2006: A Modern View of Hemostasis. Hematology/Oncology Clinics of North America, 2007, 21, 1-11.	2.2	219
15	Platelets induce sinusoidal endothelial cell apoptosis upon reperfusion of the cold ischemic rat liver. Gastroenterology, 2000, 118, 183-191.	1.3	205
16	A Cell-Based Model of Thrombin Generation. Seminars in Thrombosis and Hemostasis, 2006, 32, 032-038.	2.7	195
17	Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Alimentary Pharmacology and Therapeutics, 2007, 26, 141-148.	3.7	181
18	Safety profile of recombinant factor VIIa. Seminars in Hematology, 2004, 41, 101-108.	3.4	170

#	Article	IF	Citations
19	Thrombin Activates Factor XI on Activated Platelets in the Absence of Factor XII. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 170-177.	2.4	169
20	Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood, 1995, 86, 1794-1801.	1.4	153
21	Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. Journal of Thrombosis and Haemostasis, 2004, 2, 402-413.	3.8	153
22	Hypercoagulation and thrombophilia in liver disease. Journal of Thrombosis and Haemostasis, 2008, 6, 2-9.	3.8	152
23	Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. Blood, 2003, 101, 3008-3013.	1.4	145
24	High dose factor VIIa improves clot structure and stability in a model of haemophilia B. British Journal of Haematology, 2005, 131, 645-655.	2.5	127
25	High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. British Journal of Haematology, 2001, 114, 114-120.	2.5	126
26	Modification of Fibrinogen by Homocysteine Thiolactone Increases Resistance to Fibrinolysis:â€‰ A Potential Mechanism of the Thrombotic Tendency in Hyperhomocysteinemia. Biochemistry, 2006, 45, 2480-2487.	2.5	122
27	Hypothesis: Hyperhomocysteinemia is an indicator of oxidant stress. Medical Hypotheses, 2011, 77, 1088-1093.	1.5	113
28	Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. American Journal of Hematology, 2000, 65, 30-34.	4.1	112
29	Synergism between platelets and leukocytes in inducing endothelial cell apoptosis in the cold ischemic rat liver: a Kupffer cell mediated injury. FASEB Journal, 2001, 15, 1230-1232.	0.5	104
30	Cutaneous wound healing is impaired in hemophilia B. Blood, 2006, 108, 3053-3060.	1.4	104
31	Transmission of a procoagulant signal from tissue factor-bearing cells to platelets. Blood Coagulation and Fibrinolysis, 1996, 7, 459-464.	1.0	100
32	Newer concepts of blood coagulation. Haemophilia, 1998, 4, 331-334.	2.1	100
33	Platelet procoagulant complex assembly in a tissue factor-initiated system. British Journal of Haematology, 1994, 88, 364-371.	2.5	99
34	Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?. Thrombosis and Haemostasis, 2014, 112, 189-198.	3.4	92
35	Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia. Journal of Thrombosis and Haemostasis, 2003, 1, 300-306.	3.8	91
36	Mechanisms and monitoring of bypassing agent therapy. Journal of Thrombosis and Haemostasis, 2012, 10, 1478-1485.	3.8	91

#	Article	IF	Citations
37	Platelet Heterogeneity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 861-866.	2.4	89
38	The Factor VII-Platelet Interplay: Effectiveness of Recombinant Factor VIIa in the Treatment of Bleeding in Severe Thrombocytopathia. Seminars in Thrombosis and Hemostasis, 2000, Volume 26, 0373-0378.	2.7	87
39	From antiphospholipid syndrome to antibody-mediated thrombosis. Lancet, The, 1997, 350, 1491-1493.	13.7	85
40	Why Are Young College Women Not Using Condoms? Their Perceived Risk, Drug Use, and Developmental Vulnerability May Provide Important Clues to Sexual Risk. Archives of Psychiatric Nursing, 2006, 20, 32-40.	1.4	82
41	Coagulation Factor IXa Binding to Activated Platelets and Platelet-Derived Microparticles: A Flow Cytometric Study. Thrombosis and Haemostasis, 1992, 68, 074-078.	3.4	81
42	Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood, 2002, 100, 153-158.	1.4	79
43	New Insights into the Coagulation System and Implications for New Therapeutic Options with Recombinant Factor VIIa. Current Medicinal Chemistry, 2003, 10, 797-811.	2.4	78
44	Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high- dose factor VIIa in hemophilia [see comments]. Blood, 1994, 83, 38-42.	1.4	77
45	Tissue factor around dermal vessels has bound factor VII in the absence of injury. Journal of Thrombosis and Haemostasis, 2007, 5, 1403-1408.	3.8	77
46	The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Seminars in Hematology, 2001, 38, 6-9.	3.4	76
47	Tumor Necrosis Factor-Î± Induces Increased Hydrogen Peroxide Production and Fc Receptor Expression, but Not Increased Ia Antigen Expression by Peritoneal Macrophages. Journal of Leukocyte Biology, 1987, 42, 704-707.	3.3	75
48	Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin. Thrombosis Research, 2016, 146, 113-118.	1.7	75
49	Protease-Activated Receptor-2 Signaling Triggers Dendritic Cell Development. American Journal of Pathology, 2003, 162, 1817-1822.	3.8	74
50	The central role of thrombin in bleeding disorders. Blood Reviews, 2019, 38, 100582.	5.7	72
51	Superactivated Platelets. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1747-1752.	2.4	71
52	Novel oral anticoagulants and reversal agents: Considerations for clinical development. American Heart Journal, 2015, 169, 751-757.	2.7	69
53	Variability in platelet procoagulant activity in healthy volunteers. Thrombosis Research, 1996, 81, 533-543.	1.7	68
54	The Coagulation Cascade in Cirrhosis. Clinics in Liver Disease, 2009, 13, 1-9.	2.1	62

#	Article	IF	Citations
55	Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways. Blood, 2020, 135, 755-765.	1.4	61
56	PDGF-stimulated fibroblast proliferation is enhanced synergistically by receptor-recognized ?2-Macroglobulin. Journal of Cellular Physiology, 1990, 145, 1-8.	4.1	60
57	Analyzing fibrin clot structure using a microplate reader. Blood Coagulation and Fibrinolysis, 2002, 13, 533-539.	1.0	58
58	Reticulated platelet counts in patients undergoing autologous bone marrow transplantation: An aid in assessing marrow recovery. American Journal of Hematology, 1994, 46, 319-324.	4.1	56
59	Î±2-macroglobulin â€˜fastâ€™ forms inhibit superoxide production by activated macrophages. Biochimica Et Biophysica Acta - General Subjects, 1983, 760, 421-423.	2.4	54
60	Exposure of Mice to Topical Bovine Thrombin Induces Systemic Autoimmunity. American Journal of Pathology, 2001, 159, 1957-1969.	3.8	53
61	Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels. Molecular Therapy, 2019, 27, 1228-1241.	8.2	52
62	Adaptation to hyperoxia in the neonatal rat: Kinetic parameters of the oxygen-mediated induction of lung superoxide dismutases, catalase and glutathione peroxidase. Toxicology, 1980, 16, 215-225.	4.2	51
63	Fatal necrotizing esophagitis due toPenicillium chrysogenum in a patient with acquired immunodeficiency syndrome. European Journal of Clinical Microbiology and Infectious Diseases, 1992, 11, 1158-1160.	2.9	50
64	Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin. Rna, 2009, 15, 2105-2111.	3.5	50
65	Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces. Blood, 2002, 100, 539-546.	1.4	49
66	Platelet-dependent action of high-dose factor VIIa. Blood, 2002, 100, 364-366.	1.4	49
67	Circulating tissue factor accumulates in thrombi, but not in hemostatic plugs. Journal of Thrombosis and Haemostasis, 2006, 4, 2092-2093.	3.8	49
68	A Rapid Method to Isolate Platelets from Human Blood by Density Gradient Centrifugation. American Journal of Clinical Pathology, 1992, 98, 531-533.	0.7	46
69	Thrombin Enhances Monocyte Secretion of Tumor Necrosis Factor and Interleukin-1 Beta By Two Distinct Mechanisms. Blood Cells, Molecules, and Diseases, 1995, 21, 156-167.	1.4	45
70	Anti-heart Antibodies in Postpericardiotomy Syndrome: Cause or Epiphenomenon?. Autoimmunity, 2002, 35, 241-245.	2.6	45
71	Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. Journal of Thrombosis and Haemostasis, 2007, 5, 1577-1583.	3.8	44
72	Alterations of Fibrinogen Structure in Human Disease. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2008, 6, 206-211.	1.0	43

#	Article	IF	Citations
73	Response of blood leukocytes to thrombin receptor peptides. Journal of Leukocyte Biology, 1993, 54, 145-151.	3.3	42
74	Leukocyte chemoattractant peptides from the serpin heparin cofactor II.. Journal of Biological Chemistry, 1991, 266, 704-709.	3.4	42
75	Prophylactic correction of the international normalized ratio in neurosurgery: a brief review of a brief literature. Journal of Neurosurgery, 2011, 114, 9-18.	1.6	41
76	Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis. Blood, 2017, 129, 2161-2171.	1.4	40
77	The clotting system â€“ a major player in wound healing. Haemophilia, 2012, 18, 11-16.	2.1	39
78	The effect of factor X level on thrombin generation and the procoagulant effect of activated factor VII in a cell-based model of coagulation. Blood Coagulation and Fibrinolysis, 2000, 11, S3-S7.	1.0	38
79	Deencryption of Cellular Tissue Factor Is Independent of Its Cytoplasmic Domain. Biochemical and Biophysical Research Communications, 2000, 272, 332-336.	2.1	38
80	Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. British Journal of Haematology, 2006, 134, 314-319.	2.5	36
81	Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood, 1995, 86, 1794-801.	1.4	33
82	Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation. Thrombosis and Haemostasis, 1998, 80, 578-84.	3.4	33
83	Consequences of intraâ€articular bleeding in haemophilia: science to clinical practice and beyond. Haemophilia, 2012, 18, 112-119.	2.1	32
84	Perivascular tissue factor is down-regulated following cutaneous wounding: implications for bleeding in hemophilia. Blood, 2008, 111, 2046-2048.	1.4	31
85	Wound healing in haemophilia â€“ breaking the vicious cycle. Haemophilia, 2010, 16, 13-18.	2.1	31
86	Heparin cofactor II-proteinase reaction products exhibit neutrophil chemoattractant activity. Blood, 1989, 73, 1682-1685.	1.4	30
87	The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Disease-a-Month, 2003, 49, 14-21.	1.1	30
88	Alpha-Macroglobulin Secreted by Alveolar Macrophages Serves as a Binding Protein for a Macrophage-derived Homologue of Platelet-derived Growth Factor. American Journal of Respiratory Cell and Molecular Biology, 1989, 1, 171-179.	2.9	29
89	Platelets from Thrombocytopenic Ponies Acutely Infected with Equine Infectious Anemia Virus Are Activated in Vivo and Hypofunctional. Virology, 1999, 259, 7-19.	2.4	28
90	Rethinking the Coagulation Cascade. Japanese Journal of Thrombosis and Hemostasis, 2005, 16, 70-81.	0.1	28

#	Article	IF	Citations
91	Pro-thrombotic and pro-oxidant effects of diet-induced hyperhomocysteinemia. Thrombosis Research, 2007, 120, 117-126.	1.7	27
92	Tissue Factor in Brain Is Not Saturated With Factor VIIa. Stroke, 2009, 40, 2882-2884.	2.0	27
93	Reversal of Dabigatran Effects in Models of Thrombin Generation and Hemostasis by Factor VIIa and Prothrombin Complex Concentrate. Anesthesiology, 2015, 122, 353-362.	2.5	27
94	Coagulation in Liver Disease. Seminars in Thrombosis and Hemostasis, 2015, 41, 447-454.	2.7	27
95	Leukocyte chemoattractant peptides from the serpin heparin cofactor II. Journal of Biological Chemistry, 1991, 266, 704-9.	3.4	27
96	The Tissue Factor Pathway and Wound Healing. Seminars in Thrombosis and Hemostasis, 2018, 44, 142-150.	2.7	26
97	The Cellular Basis of Traumatic Bleeding. Military Medicine, 2004, 169, 5-7.	0.8	25
98	The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review. International Journal of Emergency Medicine, 2018, 11, 55.	1.6	25
99	Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage. Canadian Journal of Anaesthesia, 2002, 49, S7-14.	1.6	25
100	Elevated prothrombin level and shortened clotting times in subjects with type 2 diabetes. Journal of Thrombosis and Haemostasis, 2007, 5, 638-639.	3.8	24
101	Wound healing in hemophilia B mice and low tissue factor mice. Thrombosis Research, 2010, 125, S74-S77.	1.7	24
102	Vascular Localization of the Heparin-binding Serpins Antithrombin, Heparin Cofactor II, and Protein C Inhibitor. Clinical and Applied Thrombosis/Hemostasis, 1996, 2, 185-191.	1.7	23
103	Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels. Journal of Thrombosis and Haemostasis, 2013, 11, 1043-1052.	3.8	23
104	Variability in the Fibrinogen and Von Willebrand Factor Content of Cryoprecipitate: Implications for Reducing Donor Exposure. American Journal of Clinical Pathology, 1990, 93, 694-697.	0.7	22
105	Cellular Interactions in Hemostasis. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1996, 26, 12-16.	0.3	22
106	Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity. Journal of Thrombosis and Haemostasis, 2011, 9, 759-766.	3.8	22
107	Comparison of the effects of IL-1Î± and TNF-Î± on phagocyte accumulation and murine antibacterial immunity. Cellular Immunology, 1989, 123, 9-22.	3.0	21
108	Characteristics of the Chemotactic Activity of Heparin Cofactor II Proteolysis Products. Journal of Leukocyte Biology, 1990, 48, 156-162.	3.3	20

#	Article	IF	Citations
109	The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Disease-a-Month, 2003, 49, 14-21.	1.1	20
110	Practical coagulation for the blood banker. Transfusion, 2013, 53, 1594-1602.	1.6	20
111	A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagulation and Fibrinolysis, 1998, 9 Suppl 1, S15-20.	1.0	20
112	Low intensity laser therapy speeds wound healing in hemophilia by enhancing platelet procoagulant activity. Wound Repair and Regeneration, 2012, 20, 770-777.	3.0	19
113	Effect of cyclooxygenase inhibitors and protease inhibitors on phorbol-induced stimulation of oxygen consumption and superoxide production by rat pulmonary macrophages. Biochemical Pharmacology, 1982, 31, 775-780.	4.4	18
114	Inhibition of Platelet-derived Growth Factor-BB-induced Fibroblast Proliferation by Plasmin-activated Î±2-Macroglobulin Is Mediated via an Î±2-Macroglobulin Receptor/Low Density Lipoprotein Receptor-related Protein-dependent Mechanism. Journal of Biological Chemistry, 1995, 270, 6389-6395.	3.4	18
115	Animal models of bleeding and tissue repair. Haemophilia, 2008, 14, 62-67.	2.1	18
116	The Effect of Active Site-inhibited Factor VIIa on Tissue Factor-initiated Coagulation Using Platelets before and after Aspirin Administration. Thrombosis and Haemostasis, 1997, 78, 1202-1208.	3.4	18
117	Antibodyâ€Coated Erythrocytes Induce Secretion of Tumor Necrosis Factor by Human Monocytes: A Mechanism for the Production of Fever by Incompatible Transfusions. Vox Sanguinis, 1991, 60, 184-187.	1.5	17
118	Production of superoxide anion by an nadph-oxidase from rat pulmonary macrophages. FEBS Letters, 1980, 121, 352-354.	2.8	16
119	A mouse bleeding model to study oral anticoagulants. Thrombosis Research, 2014, 133, S6-S8.	1.7	16
120	Î± 2Macroglobulin-proteinase complexes stimulate prostaglandin E2 synthesis by peritoneal macrophages. Agents and Actions, 1988, 25, 360-367.	0.7	15
121	Homocysteinylated fibrinogen forms disulfide-linked complexes with albumin. Thrombosis Research, 2011, 127, 576-581.	1.7	15
122	Impact of Nonâ€“Vitamin K Antagonist Oral Anticoagulants From a Basic Science Perspective. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1812-1818.	2.4	15
123	Platelet activation in patients with thrombotic thrombocytopenic purpura. American Journal of Hematology, 1993, 42, 182-185.	4.1	14
124	Links Between the Immune and Coagulation Systems: How Do "Antiphospholipid Antibodies" Cause Thrombosis?. Immunologic Research, 2000, 22, 191-198.	2.9	14
125	Coagulation Factor Interaction with Platelets. Thrombosis and Haemostasis, 2002, 88, 179.	3.4	14
126	Heparin cofactor II and thrombin. Trends in Cardiovascular Medicine, 1994, 4, 140-146.	4.9	13

#	Article	IF	Citations
127	Laboratory Monitoring of High-Dose Factor VIIa Therapy. Annals of Internal Medicine, 2003, 139, 791.	3.9	13
128	Heparin cofactor II in atherosclerotic lesions from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Experimental and Molecular Pathology, 2009, 87, 178-183.	2.1	13
129	Platelet binding and activity of recombinant factor VIIa. Thrombosis Research, 2010, 125, S16-S18.	1.7	13
130	Coagulation factor IXa binding to activated platelets and platelet-derived microparticles: a flow cytometric study. Thrombosis and Haemostasis, 1992, 68, 74-8.	3.4	13
131	The macrophage-mediated regulation of hepatocyte synthesis of antithrombin III and Î±1-proteinase inhibitor. Thrombosis Research, 1986, 41, 707-715.	1.7	11
132	Hemostasis: Old System, New Players, New Directions. Thrombosis Research, 2014, 133, S1-S2.	1.7	11
133	The Effect of Fibrin Polymerization Inhibitors on Quantitative Measurements of Plasma Fibrinogen. American Journal of Clinical Pathology, 1987, 88, 490-493.	0.7	10
134	Platelets contain releasable coagulation factor IX antigen. Blood Coagulation and Fibrinolysis, 1993, 4, 905-910.	1.0	10
135	Human platelets express endothelial protein C receptor, which can be utilized to enhance localization of factor VIIa activity. Journal of Thrombosis and Haemostasis, 2018, 16, 1817-1829.	3.8	10
136	Fathers of modern coagulation. Thrombosis and Haemostasis, 2007, 98, 3-5.	3.4	9
137	Nanosilver composite pNIPAm microgels for the development of antimicrobial plateletâ€like particles. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2020, 108, 2599-2609.	3.4	9
138	Progressive improvement in wound healing with increased therapy in haemophilia B mice. Haemophilia, 2013, 19, 926-932.	2.1	8
139	Platelet-like particles improve fibrin network properties in a hemophilic model of provisional matrix structural defects. Journal of Colloid and Interface Science, 2020, 577, 406-418.	9.4	8
140	Production of chemotactic peptides by neutrophil degradation of heparin cofactor II. Thrombosis Research, 1990, 57, 77-85.	1.7	7
141	Localization of heparin cofactor II in injured human skin: a potential role in wound healing. Experimental and Molecular Pathology, 2003, 75, 109-118.	2.1	7
142	Differences in the metabolic response to exogenous homocysteine in juvenile and adult rabbits. Journal of Nutritional Biochemistry, 2004, 15, 96-102.	4.2	7
143	Coated platelets and severe haemophilia A bleeding phenotype: Is there a connection?. Haemophilia, 2016, 22, 148-151.	2.1	7
144	Reduced trypsin-binding capacity of Î±2-macroglobulin in the peritoneal fluid of women with endometriosis: possible relevance to alterations in macrophase function**Supported by the Career Development Program of the Veterans Administration (M.H.); the Josiah Charles Trent Foundation (A.F.H.); the Veterans Administration, research grant P01-A123308 from the National Institutes of Health and the James Swiger Hematology Research Fund (J.B.W.).. Fertility and Sterility, 1988, 50, 39-47.	1.0	6

#	Article	IF	Citations
145	Effect of interferon-Î³ and human Î±2-macroglobulin on peritoneal macrophage morphology and Ia antigen expression. Biochimica Et Biophysica Acta - Molecular Cell Research, 1990, 1051, 166-173.	4.1	6
146	Protein C inhibitor (plasminogen activator inhibitor-3) expression in the CWR22 prostate cancer xenograft. Experimental and Molecular Pathology, 2005, 79, 23-32.	2.1	6
147	Some things I thought I knew about tissue factor that turn out to be wrong. Thrombosis Research, 2008, 122, S73-S77.	1.7	6
148	A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation. Journal of Thrombosis and Thrombolysis, 2009, 28, 132-139.	2.1	6
149	Heparins: Clinical Use and Laboratory Monitoring. Laboratory Medicine, 2010, 41, 621-626.	1.2	6
150	The multiple roles of tissue factor in wound healing. Frontiers in Bioscience - Scholar, 2012, S4, 713-721.	2.1	6
151	Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding. Blood Advances, 2021, 5, 3736-3736.	5.2	6
152	Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors. Nature Communications, 2021, 12, 6912.	12.8	6
153	The Monocyte Monolayer Assay: A Noninvasive Technique for Predicting the Severity of in Utero Hemolysis. American Journal of Perinatology, 1995, 12, 157-160.	1.4	5
154	One more way that mice and men are different. Journal of Thrombosis and Haemostasis, 2005, 3, 448-449.	3.8	5
155	Biology of Coagulation and Coagulopathy in Neurologic Surgery. Neurosurgery Clinics of North America, 2018, 29, 475-483.	1.7	5
156	Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. American Journal of Hematology, 2000, 65, 30-34.	4.1	5
157	Heparin cofactor II-proteinase reaction products exhibit neutrophil chemoattractant activity. Blood, 1989, 73, 1682-5.	1.4	5
158	The effects of heparin cofactor II-derived chemotaxins on neutrophil actin conformation and cyclic AMP levels. Biochimica Et Biophysica Acta - Molecular Cell Research, 1991, 1095, 78-82.	4.1	4
159	FVIIa: you've come a long way, baby!. Blood, 2008, 112, 3002-3003.	1.4	4
160	Celecoxib does not delay cutaneous wound healing in haemophilia B mice. Haemophilia, 2009, 15, 615-616.	2.1	4
161	Inflammation does not predispose to bleeding in hemophilia. Journal of Thrombosis and Haemostasis, 2010, 8, 2583-2585.	3.8	4
162	Reversing targeted oral anticoagulants. Hematology American Society of Hematology Education Program, 2014, 2014, 518-523.	2.5	4

#	Article	IF	Citations
163	No association between donor age and recipient outcomes: transfusion of plasma in patients undergoing coronary artery bypass grafting surgery. Transfusion, 2016, 56, 1723-1729.	1.6	4
164	Heparin cofactor II-proteinase reaction products exhibit neutrophil chemoattractant activity. Blood, 1989, 73, 1682-1685.	1.4	4
165	Dysregulation of Hemostasis by Cancer. Cancer Treatment and Research, 2009, 148, 3-15.	0.5	3
166	Changes in Oxygen Consumption and Phagocytosis in Rat Pulmonary Macrophages Related to Animal Maturation. Experimental Lung Research, 1980, 1, 313-322.	1.2	2
167	Excess Factor VIII and Hypercoagulability. Journal of the American Board of Family Medicine, 2005, 18, 328-328.	1.5	2
168	Fibrinogen-Coated Nanospheres Prevent Thrombocytopenia-Related Bleeding. Biology of Blood and Marrow Transplantation, 2015, 21, S111-S113.	2.0	2
169	An activated factor VII variant with enhanced tissue factor-independent activity speeds wound healing in a mouse hemophilia B model. Journal of Thrombosis and Haemostasis, 2016, 14, 1249-1254.	3.8	2
170	Cell-Mediated Hemostasis. , 2016, , 3-14.		2
171	The Effect of Alpha2Macroglobulin-Proteinase Complexes on Macrophage IA Expression in Vivo. Immunological Investigations, 1991, 20, 33-43.	2.0	1
172	Expanding uses of high-dose factor VIIa. Blood, 2003, 101, 1666-1666.	1.4	1
173	Editorial: International normalized ratio. Journal of Neurosurgery, 2011, 114, 8.	1.6	1
174	Coated platelet assay: a feasible approach to a complicated science. Haemophilia, 2016, 22, e67-e70.	2.1	1
175	The next best thing in factor VIIa. Journal of Thrombosis and Haemostasis, 2018, 16, 1911-1913.	3.8	1
176	Cell-Mediated Hemostasis. , 2021, , 31-41.		1
177	Abstract 288: Nitric Oxide Mediates Active Downregulation of Tissue Factor Expression in Human Pericytes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, .	2.4	1
178	Reversal Of Dabigatran Anticoagulation By a 4-Factor Prothrombin Complex Concentrate: Correlation Between Effects On Parameters Of Thrombin Generation and Hemostatic Effect In Vivo. Blood, 2013, 122, 3643-3643.	1.4	1
179	Endothelial Protein C Receptor Is Expressed on Procoagulant Platelets and Contributes to Factor VIIa Binding and Activity. Blood, 2014, 124, 4224-4224.	1.4	1
180	Reaction of Fibrinogen with Homocysteine Thiolactone Mimics the Dysfibrinogenemia Produced by Hyperhomocysteinemia.. Blood, 2005, 106, 137-137.	1.4	1

#	Article	IF	Citations
181	The effects of activated factor VII in a cell-based model for tissue factor-initiated coagulation. Blood Coagulation and Fibrinolysis, 1998, 9 Suppl 1, S21-5.	1.0	1
182	Treatment of Immune-Mediated Thrombosis: A Pathogenically Oriented Regimen Proposal Based on Studies of 33 Patients With Antiphospholipid Syndrome. American Journal of Reproductive Immunology, 1992, 28, 293-293.	1.2	0
183	Inhibition of human and pig thrombin by a high-affinity nuclease-resistant RNA aptamer. Journal of the American College of Surgeons, 2000, 191, S74-S75.	0.5	0
184	The Potential Role of Factor VIIa in Transfusion Medicine. Transfusion Alternatives in Transfusion Medicine, 2003, 5, 20-22.	0.2	0
185	The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Disease-a-Month, 2003, 49, 14-21.	1.1	0
186	UNDERSTANDING AND MANAGING COAGULOPATHIC BLEEDING. Shock, 2004, 21, 149.	2.1	0
187	Regulation of Hemostasis and Thrombosis. , 2010, , 87-95.		0
188	Hemostatic properties of the FVIIa analog NN1731. Thrombosis Research, 2012, 129, S49-S50.	1.7	0
189	161: Effect of antifibrinolytic drugs on in vitro clot formation among peripartum women. American Journal of Obstetrics and Gynecology, 2015, 212, S96.	1.3	0
190	A unique protein kinaseÂCâ€dependent pathway for tissue factor downregulation in pericytes. Journal of Thrombosis and Haemostasis, 2019, 17, 670-680.	3.8	0
191	Regulation of Hemostasis and Thrombosis. , 2019, , 81-89.e2.		0
192	EPCR knockout: inflaming the discussion. Blood, 2020, 135, 2201-2202.	1.4	0
193	A commentary on â€œA rapid, sensitive and specific assay to measure TF activity based on chromogenic determination of thrombin generationâ€• Journal of Thrombosis and Haemostasis, 2022, 20, 816-817.	3.8	0